Gefarnate structure
|
Common Name | Gefarnate | ||
---|---|---|---|---|
CAS Number | 51-77-4 | Molecular Weight | 400.637 | |
Density | 0.9±0.1 g/cm3 | Boiling Point | 484.7±34.0 °C at 760 mmHg | |
Molecular Formula | C27H44O2 | Melting Point | 25°C | |
MSDS | N/A | Flash Point | 93.3±24.0 °C |
Use of GefarnateGefarnate is a drug used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome. |
Name | [(2E)-3,7-dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate |
---|---|
Synonym | More Synonyms |
Description | Gefarnate is a drug used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome. |
---|---|
Related Catalog | |
In Vitro | Gefarnate (0.001, 0.01, or 0.1 mg/mL) increases mucin-like glycoprotein secretion in a dose-dependent fashion, but the difference from the control is significant only at the concentration of 0.1 mg/mL. Gefarnate specifically stimulates the mucin-like glycoprotein secretion[1]. |
References |
Density | 0.9±0.1 g/cm3 |
---|---|
Boiling Point | 484.7±34.0 °C at 760 mmHg |
Melting Point | 25°C |
Molecular Formula | C27H44O2 |
Molecular Weight | 400.637 |
Flash Point | 93.3±24.0 °C |
Exact Mass | 400.334137 |
PSA | 26.30000 |
LogP | 10.53 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.489 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
~75% Gefarnate CAS#:51-77-4 |
Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798 |
~% Gefarnate CAS#:51-77-4 |
Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798 |
~% Gefarnate CAS#:51-77-4 |
Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798 |
~% Gefarnate CAS#:51-77-4 |
Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798 |
~% Gefarnate CAS#:51-77-4 |
Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798 |
~% Gefarnate CAS#:51-77-4 |
Literature: Nigmatov, A. G.; Serebryakov, E. P.; Yanovskaya, L. A. Pharmaceutical Chemistry Journal, 1987 , vol. 21, # 7 p. 529 - 533 Khimiko-Farmatsevticheskii Zhurnal, 1987 , vol. 21, # 7 p. 854 - 858 |
Gepharnate |
arsanyl |
(2E)-3,7-Dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate |
Gefanil |
Gefarnate [INN:BAN:JAN] |
(E)-Geranyl (E,E)-farnesylacetate |
Gefarnyl |
Osteol |
EINECS 200-121-0 |
trans-(4,5),trans-(8,9)-Farnesylessigsaeure-geranylester |
Gefarnate |
(2E)-3,7-Dimethyl-2,6-octadien-1-yl (4E,8E)-5,9,13-trimethyl-4,8,12-tetradecatrienoate |
(4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoic acid [(2E)-3,7-dimethylocta-2,6-dienyl] ester |
DA-688 |
Gefarnato [INN-Spanish] |
Geranyl farnesylacetate |
5,9,13-Trimethyl-4,8,12-tetradecatrienoic acid 3,7-dimethyl-2,6-octadienyl ester |
(4E,8E)-Farnesylacetic acid geranyl ester |
Gefarnil |
Gefarnatum [INN-Latin] |
4,8,12-Tetradecatrienoic acid, 5,9,13-trimethyl-, (2E)-3,7-dimethyl-2,6-octadien-1-yl ester, (4E,8E)- |